Thrombolytic Therapy in Acute Ischemic Stroke.

Area of Science:

• Neurology
• Cardiology
• Emergency Medicine

Background:

• Intravenous thrombolytic therapy is approved for acute ischemic stroke in major regions.
• Guidelines recommend recombinant tissue-plasminogen activator (rt-PA) within 3 hours of stroke onset, with specific contraindications.
• Despite approval, rt-PA use remains low (<5%) in the United States.

Purpose of the Study:

• To review the current status and challenges of intravenous thrombolytic therapy for acute ischemic stroke.
• To highlight the gap between rt-PA eligibility and actual patient treatment.
• To identify barriers to the adoption of thrombolytic therapy in clinical practice.

Main Methods:

• Review of published guidelines and clinical practice data regarding rt-PA administration.
• Analysis of factors influencing physician and medical center willingness to administer thrombolysis.
• Assessment of the risks associated with thrombolytic therapy, specifically hemorrhage and edema.

Main Results:

• Only a small percentage of eligible acute ischemic stroke patients receive rt-PA.
• Significant risks of fatal brain hemorrhage (5-10%) are associated with thrombolysis.
• Many healthcare providers and institutions lack the resources or willingness to administer thrombolytic drugs.

Conclusions:

• Despite its efficacy, rt-PA treatment for acute ischemic stroke faces significant underutilization.
• Barriers include physician hesitancy, institutional unpreparedness, and the inherent risks of hemorrhage.
• Strategies to improve rt-PA administration are needed to increase access to this critical stroke treatment.